Sophia GeneticsFRA:90B +6.61%72 Net Margin % is -89.09% as of Mar. 2026. GuruFocus rates FRA:90B with a GF Score™ of 72/100 and a GF Value™ of €4.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 90.72% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Sophia Genetics's Net Income for the
three
months ended in Mar. 2026 was €-16.71 Mil. Sophia Genetics's Revenue for the
three
months ended in Mar. 2026 was €18.76 Mil. Therefore, Sophia Genetics's net margin for the quarter that ended in Mar. 2026 was -89.09%.
The historical rank and industry rank for Sophia Genetics's Net Margin % or its related term are showing as below:
FRA:90B'
s Net Margin % Range Over the Past 10 Years
Min: -183.87 Med: -133.23 Max: -95.89
Current: -99.7
FRA:90B's Net Margin % is ranked worse than 90.72% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs FRA:90B: -99.70
Sophia Genetics (FRA:90B) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sophia Genetics Net Margin % Related Terms
Sophia Genetics Net Margin % Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:90B vs SLP, TBRG, CARL: Net Margin % Comparison
For the Health Information Services subindustry, Sophia Genetics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (FRA:90B) has a Net Margin % of -89.09% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #606 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 90.7%.
Is Sophia Genetics' Net Margin % too high?
Sophia Genetics' current Net Margin % is -89.09%. Based on the distribution chart, Sophia Genetics ranks #606 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Sophia Genetics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Net Margin % compare to SLP and TBRG?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #606 out of 668 companies for Net Margin %. This places Sophia Genetics in the lower half of its industry. The industry median Net Margin % is 2.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current Net Margin % is -89.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (FRA:90B) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.27, compared to a current price of €4.84 — trading 13.3% above its estimated fair value. The current Net Margin % is -89.09%. Sophia Genetics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sophia Genetics (FRA:90B), the current Net Margin % is -89.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (FRA:90B) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of €4.84 is trading 13.3% above its estimated GF Value™ of €4.27.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for FRA:90B:
Net Margin %: -89.09%
GF Value™: €4.27 vs. price of €4.84 (13.3% above fair value)
No single metric tells the full story. See the FRA:90B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
72GF Score
Get the complete analysis for FRA:90B
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:90B has been successfully added to your 
